Skip to main content
Equibles
ACRS logo

ACRS · Aclaris Therapeutics, Inc.

Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.32 -0.19 (-3.36%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$783.83M
Shares
147.20M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.32 Open$5.50 Day$5.17–5.60 52W close$1.81–6.54 Avg vol 30d2.0M Short int15.2M · 10.3% float · 8.7d Short vol51% Last earningsApr 28, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 6

Up next

Latest filing: 10-Q
filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.22M
Trailing 12 months
Net income (TTM)
−$75.74M
Trailing 12 months
Revenue growth YoY
-8.3%
Year over year
Operating margin
-1,050.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.4%
Year over year · more shares
Price change (1Y)
+169.9%
Trailing year
Short interest
10.3%
Latest settlement · 8.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +24%
above
Price vs 50-day avg −8%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 74%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −9%
trailing
6-month return +44%
trailing
YTD return +77%
this year
Relative strength +26%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.31% of float · ▲ +3.2% MoM · 8.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
149 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Strong
Gross margin 193%
EPS growth +69%
Y/Y
Free cash flow $-47.2M
Balance sheet $11.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 97%
annualized · 1-yr
Max drawdown −37%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+24% Bullish
Price vs 50-day avg
−8% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
74% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow Accumulating
+9% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.31% of float · ▲ +3.2% MoM · 8.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
149 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $5 · 74% Range high $7
vs 200-day avg +24% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACRS
Aclaris Therapeutics, Inc.
this stock
$783.83M +76.7% -58.2% — 10.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
149
% held
81.5%
Net QoQ
+10.3M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
138
View
Short & Settlement
Short Interest Rising
Shares short
15.2M
Days to cover
8.7d
Change
+470.1K sh
View
Short Volume
Short vol %
51%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
21
Value
$124
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
45.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.8M
Net income (FY)
$-64.9M
EPS diluted
$-0.53
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
16
View
Proposed Sales
Value
$31.7K
Shares
6.0K
Filed
Oct 23, 2023
View
Exempt Offerings
Offering
$80.0M
Filed
Dec 4, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
ACRS -10.6% -9.2% +44.2% -12.1% +76.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -9.4% -7.5% +26.3% -11.7% +64.7%
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 79 filings 79 filers Visit website Investor relations